Elisa Teyssou
Overview
Explore the profile of Elisa Teyssou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guiraud V, Sauce D, Bittar R, Fernandez J, Thevenet H, Teyssou E, et al.
Infect Dis Now
. 2025 Feb;
55(2):105040.
PMID: 39961547
Introduction: Positive cardiovascular and renal outcomes associated with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) use are attributed to their anti-inflammatory properties. Persistent immune activation accounts for part of the elevated...
2.
Soulie C, Agher R, Fauchois A, Abdi B, Wirden M, Teyssou E, et al.
J Antimicrob Chemother
. 2024 Dec;
80(3):697-700.
PMID: 39704180
Background: We aimed to determine how non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance profiles have changed over the last decade in people living with HIV (PLWHIV) experiencing virological failure on all...
3.
Abdi B, Palich R, Seang S, Fauchois A, Cocherie T, Faycal A, et al.
JAC Antimicrob Resist
. 2024 Dec;
6(6):dlae194.
PMID: 39659644
Introduction: We assessed the kinetics of the clearance of integrase strand transfer inhibitors resistance mutations (INSTIs-RMs) and associated factors from people living with HIV (PWH) displaying suppressed viral replication after...
4.
Teyssou E, Soulie C, Fauchois A, Palich R, Nouchi A, Sayon S, et al.
J Antimicrob Chemother
. 2024 May;
79(7):1673-1676.
PMID: 38804140
Objectives: Resistance associated mutations (RAMs) are archived in the HIV reservoir and can re-emerge with an inappropriate ART use limiting treatment options. However, recent studies, using ultra-deep sequencing (UDS), showed...
5.
Giammarino F, De Salazar A, Malet I, Vinuela L, Fuentes A, Saladini F, et al.
J Infect Dis
. 2024 Jan;
229(6):1796-1802.
PMID: 38206187
Background: Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine. Methods: Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and...
6.
Ratouit P, Malet I, Soulie C, Denis J, Legrand R, Teyssou E, et al.
Int J Antimicrob Agents
. 2023 Nov;
63(1):107026.
PMID: 37926272
No abstract available.
7.
Teyssou E, Marot S, Gothland A, Malet I, Zafilaza K, Leducq V, et al.
J Infect
. 2023 Apr;
87(1):62-63.
PMID: 37060923
No abstract available.
8.
De Salazar A, Vinuela L, Fuentes A, Teyssou E, Charpentier C, Lambert-Niclot S, et al.
Clin Infect Dis
. 2022 Dec;
76(9):1628-1635.
PMID: 36571282
Background: We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and of clinically relevant resistance (CRR) in newly diagnosed...
9.
Teyssou E, Marot S, Cocherie T, Fauchois A, Abdi B, Todesco E, et al.
Infect Dis Now
. 2022 Nov;
53(1):104629.
PMID: 36323397
Objectives: We aimed to characterize and compare the viral loads (VL) of the Omicron BA.1 and BA.2 lineages and the Delta variant in nasopharyngeal samples from newly diagnosed COVID-19 patients...
10.
Santoro M, Armenia D, Teyssou E, Santos J, Charpentier C, Lambert-Niclot S, et al.
J Glob Antimicrob Resist
. 2022 Aug;
31:52-62.
PMID: 35948240
Objectives: The aim of this study was to assess the efficacy of dolutegravir plus lamivudine (DTG+3TC) in a large set of virologically suppressed HIV-1 infected individuals with or without past...